What Does PCO Mean and How Is It Different From PCOS?

PCO stands for polycystic ovaries, a term describing what ovaries look like on ultrasound when they contain a large number of small follicles. PCOS, polycystic ovary syndrome, is a hormonal and metabolic condition diagnosed when someone has a combination of symptoms including irregular periods, elevated androgens, and often that same polycystic ovary appearance. The critical difference is that PCO is an anatomical finding, while PCOS is a clinical syndrome. Plenty of women have polycystic-looking ovaries without ever developing the syndrome, and that distinction matters more than many people realize.

The Ultrasound Appearance That Started the Confusion

When a doctor performs a transvaginal ultrasound and sees an ovary with a high number of small antral follicles or an enlarged volume, they may describe it as a “polycystic ovary.” The name is somewhat misleading because these are not true cysts. They are immature follicles, the tiny fluid-filled sacs that normally develop each cycle, just present in greater numbers than usual. The original Rotterdam consensus in 2003 defined a polycystic ovary as one with 12 or more follicles measuring 2 to 9 mm, or an ovarian volume greater than 10 cubic centimeters.¹ That threshold turned out to be too low. As ultrasound technology improved and image resolution got sharper, more and more healthy, regularly cycling women met the cutoff. Updated guidelines in 2018 raised the follicle count threshold from 12 to 20 when using modern high-frequency probes.²

Even with that higher bar, ultrasound evidence of polycystic ovaries remains common. Studies using transvaginal imaging estimate that at least one in five young women has polycystic ovarian morphology.³ Most of those women have no symptoms, ovulate normally, and would never know their ovaries looked any different without an ultrasound. The commonness of the finding in otherwise healthy women is exactly why experts have questioned whether ovarian morphology alone should even factor into diagnosing the syndrome.⁴

How PCOS Is Actually Diagnosed

PCOS is not diagnosed by ultrasound alone. Under the widely used Rotterdam criteria, a person needs at least two of three features: irregular or absent ovulation, clinical or biochemical signs of excess androgens, and polycystic ovarian morphology on imaging. Other conditions that could explain the symptoms, such as thyroid disease or adrenal problems, must be ruled out first. This means someone with polycystic ovaries on ultrasound but regular cycles and normal androgen levels does not have PCOS by any standard diagnostic framework.

The “syndrome” part of PCOS is doing a lot of work in that name. It signals that this is a cluster of related problems, not a single anatomical feature. The androgens, the disrupted cycles, the metabolic changes, and the ovarian morphology tend to travel together, but they do not always show up in the same combination. That variability is what makes diagnosis tricky and what makes the PCO-versus-PCOS distinction so important in practice.

Why the Naming Overlap Causes Real Problems

The fact that “polycystic ovary” appears in both terms has caused decades of confusion for patients and clinicians. A woman might get an ultrasound for an unrelated reason, hear the phrase “polycystic ovaries,” and leave the appointment believing she has PCOS. That misunderstanding can trigger unnecessary anxiety about fertility, metabolic risk, and long-term health. Researchers have openly argued that PCOS should be renamed to better reflect its hormonal and metabolic core rather than an ovarian appearance that many healthy women share.⁵ The condition was originally called Stein-Leventhal syndrome after the doctors who described it in the 1930s, and some specialists have suggested returning to an eponym or adopting a name centered on hyperandrogenism, which more accurately captures what drives the condition.

A task force from the Androgen Excess and PCOS Society reviewed the evidence and concluded that polycystic ovarian morphology, in the absence of other symptoms, does not clearly associate with significant health consequences, though inconsistent definitions across studies make it hard to say that with complete certainty.⁶ In other words, if all you have is the ovarian appearance and nothing else, it is probably not something that requires treatment or monitoring in the way PCOS does.

The Metabolic Picture Is More Complicated Than You Might Expect

Here is where the story gets a bit unsettling. While having polycystic ovaries alone does not mean you have PCOS, there is evidence that women with PCO morphology are not metabolically identical to women with completely typical-looking ovaries. One study compared women with polycystic ovaries but no excess androgens to women with full PCOS and to a reference group. Apart from higher androgen concentrations in the PCOS group, the researchers found no significant differences between the PCO and PCOS groups in fasting insulin, glucose metabolism, sex hormone-binding globulin, gonadotropins, or blood lipid profiles. Both groups showed disturbances compared to the reference subjects.⁷

That finding has been debated and has not led to a blanket recommendation to screen every woman with PCO morphology for metabolic problems. The task force report mentioned above expressed caution about drawing strong conclusions given the inconsistencies in how PCO has been defined across studies. Still, it suggests the line between “just the appearance” and “the syndrome” may not be as clean as we would like. The ovarian morphology could be an early visible marker of underlying metabolic tendencies that have not yet produced diagnosable symptoms.

What Drives the Syndrome

PCOS has two interlocking hormonal engines: excess androgens and insulin resistance. The relationship between them creates a feedback loop. Insulin resistance pushes the body to produce more insulin, and elevated insulin stimulates the ovaries’ theca cells to churn out more androgens. That excess androgen production disrupts normal follicle development, leading to anovulation and the accumulation of small, stalled follicles that give the ovary its characteristic appearance.⁸ The androgens, in turn, worsen insulin resistance, and the cycle amplifies.

There is growing evidence that hyperandrogenism is not just a feature of PCOS but may actually be a driving cause.⁹ This is relevant to the PCO-versus-PCOS question because it underscores why the androgen piece matters so much diagnostically. Without elevated androgens (either measured in the blood or showing up as excess hair growth and acne), the hormonal engine that makes the syndrome harmful is not clearly running. PCO morphology without androgen excess looks anatomically similar but lacks the hormonal driver that produces the downstream metabolic and reproductive consequences.

PCOS Is Not One Condition

Even within PCOS itself, people experience widely different versions of the syndrome. The Rotterdam criteria allow for four recognized phenotypes depending on which combination of features is present:

• Phenotype A: irregular cycles, excess androgens, and polycystic ovarian morphology (the “classic” or full-blown presentation)
• Phenotype B: irregular cycles and excess androgens, but ovaries look normal on ultrasound
• Phenotype C: excess androgens and polycystic ovarian morphology, but regular ovulatory cycles
• Phenotype D: irregular cycles and polycystic ovarian morphology, but no androgen excess

In clinical studies, the classic phenotype A is the most common, making up about two-thirds of diagnosed cases in one prospective study.¹⁰ The phenotypes with androgen excess tend to carry the highest metabolic risk. In that same study, about half of women with the hyperandrogenic-plus-oligo-ovulation phenotype met criteria for metabolic syndrome, compared with only about one in ten in the non-androgenic phenotype. A cross-sectional study found that the classic phenotype also had the most pronounced hormonal disruption, including the highest levels of luteinizing hormone and testosterone, while the non-androgenic phenotype showed markedly less hormonal and metabolic disturbance.¹¹

Phenotype D is the one that sits closest to the PCO-only group, because it includes polycystic morphology and cycle irregularity but no androgen excess. Some researchers have questioned whether this phenotype truly belongs under the PCOS umbrella at all, given that its metabolic profile is milder. It is a gray zone, and it highlights that the boundary between PCO and PCOS is not a bright line but a spectrum.

What PCO and PCOS Mean for Fertility

PCOS is the most common cause of anovulatory infertility, but that does not mean every woman with the diagnosis struggles to conceive. Many ovulate on their own some of the time. Women with isolated PCO morphology who ovulate regularly are in a different situation: their fertility is generally similar to women with completely normal-appearing ovaries.

In IVF settings, both groups tend to produce more eggs than women with typical ovarian anatomy because the high follicle count translates to a strong response to stimulation medications. However, the outcomes diverge in important ways. One study found that women with isolated PCO had similar ovarian response and similar oocyte quality to women with PCOS, but significantly lower miscarriage rates than the PCOS group. The researchers suggested that factors beyond egg quality, likely the hormonal and metabolic environment of PCOS, contribute to the higher miscarriage risk.¹²

Another study of IVF outcomes found that women with isolated PCO had a cumulative live birth rate of about 60%, compared with 50% for the PCOS group and roughly 48% for controls. The PCOS group also had a notably higher miscarriage rate and a higher incidence of moderate to severe ovarian hyperstimulation syndrome.¹³ The takeaway is that having polycystic ovaries without the syndrome may actually be a slight advantage in fertility treatment, giving you a high egg yield without the metabolic complications that drag down PCOS outcomes.

Separately, a comparison of IVF patients found that women with ovulatory PCO had lower body mass index, lower testosterone, and lower baseline luteinizing hormone than the PCOS group, confirming that the endocrine profiles are genuinely different even when the ultrasound picture looks similar. Fertilization and cleavage rates were somewhat lower in the PCOS group, though ultimately, clinical pregnancy rates after embryo transfer were comparable across groups.¹⁴

Why Diagnosing Teens Is Especially Tricky

Adolescence is a minefield for PCOS diagnosis. Irregular periods are completely normal in the first few years after menarche while the hypothalamic-pituitary-ovarian axis matures. Acne is near-universal. And here is the problem: many healthy adolescents have polycystic ovarian morphology on ultrasound as a normal developmental feature.¹⁵ Using the adult Rotterdam criteria to diagnose PCOS in a 14-year-old risks massive overdiagnosis.

Current international guidelines now explicitly recommend that pelvic ultrasound should not be used for PCOS diagnosis in adolescents. They also advise against using anti-Müllerian hormone levels, another marker that reflects follicle count, for the same reason.¹⁶ Instead, the diagnosis should rely on documented irregular cycles (defined by age-specific thresholds that account for pubertal development) along with clear evidence of hyperandrogenism, confirmed either through physical signs like significant hirsutism and severe acne or through validated lab tests. Irregular cycles in the first year after menarche are considered normal pubertal transition and should not count toward diagnosis.¹⁷

This matters to the PCO-versus-PCOS conversation because a teenager told she has “polycystic ovaries” on a scan done for another reason might spiral into fear about PCOS, when in reality her ovaries look the way many healthy adolescent ovaries look. The guidelines exist precisely to prevent that kind of false alarm.

Long-Term Health Risks and Why the Distinction Matters

The full PCOS diagnosis carries real long-term health implications beyond irregular periods and difficulty conceiving. The combination of chronic anovulation, unopposed estrogen exposure, insulin resistance, elevated androgens, and obesity all contribute to increased risks of endometrial hyperplasia and endometrial cancer.¹⁸ Women with PCOS also face higher rates of type 2 diabetes, cardiovascular risk factors, and gestational complications. The metabolic syndrome data from the phenotype studies mentioned earlier show that these risks scale with the severity of the hormonal picture, particularly with androgen excess.

For women with isolated PCO morphology, the long-term picture is less clear. Some evidence points to subtle metabolic differences compared to women with completely typical ovarian anatomy, but whether those differences translate to meaningful disease risk over decades is genuinely uncertain. In practical terms, if you have been told you have polycystic ovaries but your cycles are regular, your androgen levels are normal, and you have no metabolic symptoms, there is no current guideline recommending that you receive the same monitoring or treatment as someone diagnosed with the full syndrome.

An Evolutionary Puzzle

One question that has nagged researchers is why PCOS persists at such high prevalence given that it is the leading cause of anovulatory infertility. From a purely evolutionary standpoint, a condition that impairs fertility should become less common over generations, not more. Several theories attempt to explain the paradox. One influential hypothesis frames PCOS as the result of “thrifty” genes that provided survival advantages during periods of nutritional scarcity: stronger muscles, moderate abdominal fat storage, and reduced insulin sensitivity, all of which would have helped conserve energy. In environments with limited food, these traits would be advantageous. Expose them to unlimited calories and sedentary lifestyles, the argument goes, and the same genetic program produces full-blown PCOS with insulin resistance and infertility.¹⁹

Genetic studies have added weight to this idea by showing that PCOS susceptibility loci are shared across populations of Chinese and European ancestry, suggesting these genetic variants have been around for more than 50,000 years, predating the migration of modern humans out of Africa.²⁰ The genes did not persist despite causing infertility; they persisted because the metabolic traits they coded for were worth keeping for most of human history. The infertility piece is a modern consequence of ancient adaptations colliding with modern abundance. If this framework holds, it also helps explain why PCO morphology is so common in otherwise healthy women: the underlying genetic architecture is widespread, and the ovarian appearance may reflect a mild version of the same metabolic programming that, when fully activated by environmental triggers, produces the clinical syndrome.